Jeff Aronin is co-founder and non-executive chairman of Castle Creek Pharmaceuticals. Since 2010 Mr. Aronin has been chairman and chief executive officer of Paragon Biosciences, a global healthcare development and biopharmaceutical investment firm. He has been chairman of several Paragon portfolio companies including Harmony Biosciences, and previously Marathon Pharma, a research based prescription biopharmaceutical company.
From 2000 to 2009, Mr. Aronin was president and chief executive officer of Ovation Pharmaceuticals Inc., a biopharmaceutical company he founded in 2000. In 2009, Ovation Pharmaceuticals was acquired by Lundbeck, Inc. Mr. Aronin served as president and chief executive officer of Lundbeck, Inc. during its acquisition and integration of Ovation Pharmaceuticals.
Mr. Aronin has experience as a chief executive officer leading several global biopharmaceutical companies. His skills include strategic and business development, finance and brand marketing. He brings valuable leadership experience and knowledge in the operations and day-to-day management of a global corporation in a regulated industry. Mr. Aronin also has experience in the structuring and execution of strategic corporate transactions, including mergers and acquisitions.
Ari Kellen, MD, is a seasoned senior executive with over three decades of health care industry experience, both in management consulting and in major global P&L and operational roles.
Dr. Kellen trained and worked as a physician in South Africa while also running a large segment of a 1,000 bed teaching hospital. After being recruited by McKinsey & Company, he spent 23 years serving health care clients around the world. Dr. Kellen served for more than a decade as a senior McKinsey partner, advising CEOs and Board members at large industry-leading healthcare companies and small rapidly growing entities. His experience spans biotechnology, medical device, payor and provider organizations, and includes work focused on mergers and acquisitions, business development, new company spin-outs, corporate and business unit level turnarounds, R&D portfolio strategy, and product/therapeutic area growth strategies. Dr. Kellen also played significant roles in McKinsey helping to build the Firm over 20 years including senior client leadership roles in Health Care, leading the Global Innovation Practice, and co-chairing the Firm’s Partner Review Committee.
In 2014 Dr. Kellen was recruited to Bausch + Lomb/Valeant where he ran a multibillion dollar P&L for three years across the US and Latin America. As EVP and General Manager of US Bausch + Lomb, he successfully launched and commercialized new products in Pharmaceuticals, Surgical, and Vision Care/Contact Lenses. He led global portfolio assessment for B+L including internal R&D development and external business acquisition. At varying points during his tenure at the company he was responsible for brand and portfolio management across several additional therapeutic areas including Dermatology and GI. Dr. Kellen was also responsible for leading the US R&D organization to advance more than 100 active R&D projects across Dermatology, Ophthalmology, Oncology, Gastroenterology and Consumer products.
Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.
Ms. Melincoff currently sits on the board of directors of Kamada, Photocure ASA, and Collegium Pharmaceutical, Inc. and is an advisor to Phase 1 Ventures and Verge Genomics. She was a board member of Tobira Therapeutics from 2014-2016 when it was acquired by Allergan for $1.7B. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc. a UK- specialist healthcare company with a portfolio of Interventional Medicine products designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins, and a Specialty Pharmaceuticals portfolio offering antidotes that alleviate toxicity and treat rare conditions.
From September 2004 to the December 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, she led the Strategic Investment Group (SIG), Shire’s $50MM corporate venture fund which was started in 2010. She served as a board member/board observer at DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciencs, Naurex Inc. (acquired by Allergan) and Enterome. During her tenure, she was involved in numerous licenses, product divestments, co- promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company within two years of the first transaction. Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.
Prior to joining Shire, Ms. Melincoff was Vice President of Business Development at Adolor Corporation, a biopharmaceutical company focused in the development of pain management products that was acquired by Cubist Pharmaceuticals and then Merck. Over the five years that Ms. Melincoff worked at Adolor, the company grew from 22 employees to over 150 employees. She was involved in helping the company launch a successful IPO and in raising over $300 million. Ms. Melincoff was responsible for crafting the collaboration agreement with GlaxoSmithKline for Entereg. This transaction included a $50 million upfront payment and potential milestones of $210 million, and was nominated for the “Allicense Deal of the Year” in 2004.
Ms. Melincoff worked for Eastman Kodak for over ten years in a number of their health care companies, including Eastman Pharmaceuticals which acquired Sterling Drug. She was the Director of Business Development at NanoSystems, a spin-out from Kodak that specialized in nanotechnology drug delivery. She was a key member of the management team which successfully built the business from a start-up to cash flow positive in less than five years and then sold the company for $175 million.
Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).
Andy Pasternak is a partner in Bain & Company’s Chicago office. He is Bain’s Healthcare Practice Leader for the Americas, and is also a member of the M&A Practice.
Andy has nearly 20 years management consulting experience in the healthcare sector, advising large pharmaceutical companies, medical technology companies, biotechnology firms, private investment funds, NGOs and government agencies. He holds deep expertise in growth strategy, market entry, competitive strategy, M&A, organizational design, operational strategy and performance improvement.
In the pharmaceutical space, Andy has worked across a wide range of specialty Therapeutic Areas (including rare diseases) and Functions, including Commercial, Operations, and R&D. In addition, Andy is an internationally recognized strategy consultant in the areas of vaccines and infectious diseases.
Finally, Andy is one of Bain’s leading experts on complex M&A transactions, in particular large corporate separations/spin-offs, divestitures and integrations of carve-outs. Andy’s experience in this area is wide-ranging across strategic, organizational, operational and transactional issues.
Prior to joining Bain in 2008, Andy was a founding partner in the Health & Life Sciences Practice at Oliver Wyman, a global management consultancy. He also worked in the Corporate Finance Group of J.P. Morgan Securities.
Andy earned an MBA from the University of Chicago Graduate School of Business and a BA in Economics from Northwestern University.
Jim Robinson is a respected and proven health care executive and passionate leader who was named president of Astellas Americas on April 1, 2016. In this role, Robinson is responsible for the company’s growing operations in North and South America. Prior to this promotion, Robinson led the company’s pharmaceutical commercial organization in the U.S., a role that he held since 2013. Robinson is also the executive sponsor of Astellas’ African American employee resource group.
Robinson’s nearly 25-year career spans a variety of diverse disciplines within the health care industry, including sales, marketing, new product planning, market access, reimbursement, state government affairs and managed markets. He joined Astellas in 2005 as vice president of health systems. Robinson has led commercial efforts in a wide range of therapeutic areas throughout his career, including virology, oncology, cardiovascular, urology, dermatology and anti-infectives.
Prior to joining Astellas, he served as an executive at the former Schering-Plough Corporation, which was acquired by Merck & Company in 2009. Beginning his career as a sales representative in 1992, he quickly advanced through the corporation, rising to vice president in charge of hepatitis sales and managed care. In this position, Robinson led the largest specialty pharmaceutical sales division within Schering-Plough.
Robinson contributes his vision and expertise to the pharmaceutical industry and the business community by serving on several boards, including the Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors. He also serves as chairman of the PhRMA State Committee, providing direction on the trade association’s state-level policy and legislative priorities, and sits on the Board of the Executive’s Committee. Robinson is a member of The Commercial Club of Chicago and serves on the BioScience Council for ChicagoNEXT, a private-public partnership dedicated to expanding Chicago’s business climate and driving growth and opportunity in science, technology, innovation and entrepreneurship. Robinson is a founding member and serves on the board of directors of MATTER, a group of leaders passionate about creating products and services that advance the healthcare industry. He is also on the Board of Directors for the Chicago Botanic Garden and Museum of Science and Industry Chicago.
Robinson is a graduate of DePaul University, Chicago, Illinois. A native of Skokie, Illinois, Robinson currently resides in Kenilworth, Illinois.
Scott Serota is President and Chief Executive Officer of the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies. The Blue Cross and Blue Shield System is the nation’s largest health insurer, covering nearly 106 million members—one-in-three of all Americans.
Serota was named BCBSA President and CEO in 2000, after serving four years as a senior executive, including two years as Chief Operating Officer. Before that, he was Executive Vice President for system development, responsible for new business, strategy and the BCBS Technology Evaluation Center, the nation’s leading source for evaluating the safety and efficacy of emerging medical treatments.
Prior to joining BCBSA, Serota was President and CEO of Chicago-based Rush Prudential Health Plans, where he led the integration of Rush-Presbyterian-St. Luke’s Medical Center Health Plans and The Prudential. Earlier in his career, Serota also created and led Physicians Preferred Health Inc., a Missouri-based PHO.
Serota is a founding member of the National Business Group on Health’s Institute on Healthcare Costs and Solutions, a board member of BCS Financial Corporation and the Brain Research Foundation, advisory board member of Marathon Pharmaceuticals, and board chairman of Plans’ Liability Insurance Company. He also serves on the Leadership Council of the Healthcare Financial Management Association, the American College of Healthcare Executives, the Dean’s Leadership Council for the College of Science at Purdue University and the Washington University School of Medicine National Council.
Serota was appointed by President George W. Bush to the Policy Committee of the White House Conference on Aging—advising the Administration and Congress on policies, programs and services affecting the nation’s older citizens—and served as chairman of the Subcommittee on Health.
He also was a charter member of the American Health Information Community, a federally chartered commission formed to work with former Health and Human Services Secretary Michael Leavitt to advance health information technology, including electronic health records.
Among civic leadership roles, Serota serves on the CEO Advisory Board for Building a Healthier Chicago. He is a frequent featured speaker at leading business and industry forums, and has spoken at the U.S. Chamber of Commerce, the Detroit Economic Club, the Executives Club of Chicago, the Jonathan Club in Los Angeles and the World Healthcare Congress in Washington, D.C.
Serota earned a bachelor’s degree from Purdue University and a master’s in health administration and planning from the Washington University School of Medicine. He holds an honorary doctorate of science from Purdue University and has been named a distinguished alumnus of both Purdue and Washington University.
Shlomo Yanai has been President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 till mid 2012. Under his leadership, Teva Revenues rose from $8.4 billion in 2006 to ~$18.3 billion in 2011. Net profit rose from $1.9 billion in ~$4.4 billion in 2011. As Teva CEO, Mr. Yanai was Ranked 20th in Fortune’s Top CEO List in 2010.
Prior to joining Teva, Mr. Yanai was the President & CEO of Makhteshim Agan Industries (Agrochemicals) from 2003 till 2006 where he was also the Chairman of the Board of Makhteshim Chemical Works Ltd., Agan Chemical Manufacturers Ltd, Milenia Agro Chemicals and Aroma Fine Chemicals Ltd.
Mr. Yanai is currently the Chairman of the Board of the Cambrex Corporation, chairman of the Board of Protalix Biotherapeutics, a board member at Q holdings and a senior advisor at Moelis & Company. Mr. Yanai was also Vice Chairman of the Rothschild Caesarea Foundation, a board member of Perrigo Company, Sagent Pharmaceuticals, Lumenis, Elisra (high-tech defense electronic devices), Bank Leumi Le-Israel (Israel’s second largest bank) and I.T.L. Optronics Ltd.
Shlomo Yanai is a graduate of the Harvard Business School’s AMP program (2001). Holds a Master’s degree (MPA) from the George Washington University in National Resource Administration (1990). His B.A. cum laude is in Political Science and Economics from Tel Aviv University (1983), and he is also a graduate of the U.S. National Defense University- War College (1989).
2012 – Honorary doctorate from Bar-Ilan University
2005 – Max Perlman Award for Excellence in Global Business Management (Tel Aviv University)
1973 – IDF Medal of Valor.
In addition, he was a member of the Board of Governors of the Technion (Israel Institute of Technology) as well as an honorary member of the board of The Institute for Policy and Strategy of the Interdisciplinary Center (IDC), Herzliya.